SEARL Pharmaceuticals: Major
Health Technology
Mkt Cap
52.2B
P/E (TTM)
44.17
EPS
-2.36
ROE
6.59%
Div Yield
—
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Return on Equity (ROE) | 2.44% | 3.18% | -0.34% | 8.67% | 17.92% | |
| Return on Assets (ROA) | 1.38% | 1.56% | -0.17% | 4.43% | 9.81% | |
| Return on Invested Capital | 2.30% | 2.74% | -0.27% | 6.43% | 14.35% | |
| Gross Margin | 48.64% | 45.60% | 43.50% | 42.69% | 45.44% | |
| Operating Margin | 12.79% | 15.74% | 14.32% | 19.72% | 21.76% | |
| EBITDA Margin | 15.42% | 18.58% | 16.95% | 21.71% | 23.55% | |
| Net Margin | 2.76% | 3.37% | -0.39% | 7.86% | 14.03% | |
| Pre-Tax Margin | 5.35% | 4.13% | 0.74% | 12.24% | 19.20% | |
| Liquidity | ||||||
| Current Ratio | 1.63 | 1.13 | 1.36 | 1.71 | 1.65 | |
| Quick Ratio | 1.26 | 0.91 | 1.03 | 1.27 | 1.22 | |
| Leverage | ||||||
| Debt / Equity | 0.25 | 0.41 | 0.66 | 0.67 | 0.69 | |
| Debt / Assets | 0.16 | 0.21 | 0.31 | 0.34 | 0.35 | |
| LT Debt / Equity | 0.00 | 0.12 | 0.20 | 0.32 | 0.38 | |
| LT Debt / Assets | 0.00 | 0.06 | 0.10 | 0.16 | 0.20 | |
| Net Debt | 7.47B | 12.84B | 19.22B | 18.76B | 17.23B | |
| Total Debt | 7.97B | 13.24B | 19.65B | 19.11B | 17.58B | |
| Efficiency | ||||||
| Asset Turnover | 0.50 | 0.46 | 0.43 | 0.56 | 0.70 | |
| Inventory Turnover | 3.02 | 2.66 | 1.98 | 2.76 | 2.86 | |
| Per Share | ||||||
| Book Value Per Share | 54.55 | 55.30 | 64.07 | 61.33 | 54.72 | |
| Tangible Book Per Share | 47.74 | 47.44 | 29.50 | 26.71 | 21.29 | |
| Cash Per Share | 0.85 | 0.73 | 0.89 | 0.75 | 0.79 | |
| Total Debt Per Share | 13.56 | 24.04 | 40.61 | 40.89 | 38.78 | |
| Working Capital Per Share | 16.91 | 3.90 | 18.56 | 23.27 | 18.36 | |
| Shares & Market | ||||||
| Total Shares Outstanding | 588,218,731 | 588,218,731 | 467,352,670 | 467,352,672 | 467,352,531 | |
| Market Cap | 44.86B | 29.22B | 14.95B | 34.02B | 58.24B | |
| Enterprise Value | 53.13B | 42.12B | 36.44B | 54.81B | 74.25B | |
| Employees | 3,663 | 3,375 | 3,363 | 3,508 | 3,262 | |
| Shareholders | 21,458 | 21,458 | 21,458 | 21,458 | 21,458 | |